The other reason explains that NCI-H1703′s squamous cell carcinoma–basal cell cancer identity predisposes sensitivity to SOX2 downregulation as part of the response we saw for chelerythrine chloride treatments [43,44,45]. This evidence concerns the gene SOX2 and squamous cell carcinoma.